Ingenuity's Path Designer is Selected as Best New Product By Life Science Community at 2008 Molecular Medicine Conference

Ingenuity Systems and Pfizer Announce Strategic Partnership for Pathway Analysis

Ingenuity Systems Delivers Key Milestones in FDA Collaboration to Facilitate Genomic Data Review

Ingenuity Systems Extends Enterprise-Level Software Agreement With GlaxoSmithKline

Ingenuity Releases Newest Version of IPA with Pathway Publishing Tool

Read the GEN article on how IPA facilitates the biomarker discovery process

Bioinformatic identification of FGF, p38-MAPK, and calcium signaling pathways associated with carcinoma in situ in the urinary bladder

BMC Cancer, 2008, 8:37 (31 January 2008)

Researchers from the Department of Genetics and Biotechnology, University of Aarhus, Denmark have developed a new way to predict the presence or absence of carcinoma in situ (CIS) in patients diagnosed with certain types of bladder cancer. Instead of focusing on the best individual markers of bladder cancer, they used Ingenuity Pathways Analysis (IPA) to study the involvement of a panel of transcription factors within canonical signaling pathways. IPA identified four signaling pathways where the transcription factors behaved coherently, indicating the whole pathway was affected. Three of these identified pathways were able to classify tissue samples according to CIS status significantly.

» Link to article synopsis
» Search Publications